Literature DB >> 21056661

Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1α in a low androgen environment.

Takakazu Mitani1, Ryoichi Yamaji, Yasuki Higashimura, Naoki Harada, Yoshihisa Nakano, Hiroshi Inui.   

Abstract

The androgen receptor (AR) acts as a ligand-dependent transcriptional factor controlling development or progression of prostate cancer. Androgen ablation by castration is an effective therapy for prostate cancer, whereas eventually most of the tumors convert from a hormone-sensitive to a hormone-refractory disease state and grow even in a low androgen environment (e.g., 0.1nM 5α-dihydrotestosterone (DHT)) like the castration-resistant stage. Androgen ablation results in hypoxia, and solid tumors possess hypoxic environments. Hypoxia-inducible factor (HIF)-1, which is composed of HIF-1α and HIF-1β/ARNT subunits, functions as a master transcription factor for hypoxia-inducible genes. Here, we report that hypoxia enhances AR transactivation in the presence of 0.05 and 0.1nM DHT in LNCaP prostate cancer cells. siRNA-mediated knockdown of HIF-1α inhibited hypoxia-enhanced AR transactivation. Its inhibition by HIF-1α siRNA was canceled by expression of a siRNA-resistant form of HIF-1α. HIF-1α siRNA repressed hypoxia-stimulated expression of the androgen-responsive NKX3.1 gene in the presence of 0.1nM DHT, but not in the absence of DHT. In hypoxia, HIF-1α siRNA-repressed AR transactivation was restored in mutants in which HIF-1α lacked DNA-binding activity. Furthermore, a dominant negative form of HIF-1α canceled hypoxia-enhanced AR transactivation, and HIF-1β/ARNT siRNAs had no influence on hypoxia-enhanced AR transactivation. These results indicate that hypoxia leads to HIF-1α-mediated AR transactivation independent of HIF-1 activity and that HIF-1β/ARNT is not necessarily required for the transactivation.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056661     DOI: 10.1016/j.jsbmb.2010.10.009

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  30 in total

Review 1.  Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment.

Authors:  Gagan Deep; Gati K Panigrahi
Journal:  Crit Rev Oncog       Date:  2015

2.  Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Authors:  Elena V Fernandez; Kelie M Reece; Ariel M Ley; Sarah M Troutman; Tristan M Sissung; Douglas K Price; Cindy H Chau; William D Figg
Journal:  Mol Pharmacol       Date:  2015-03-31       Impact factor: 4.436

3.  Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics.

Authors:  Gagan Deep; Rahul Kumar; Dhanya K Nambiar; Anil K Jain; Anand M Ramteke; Natalie J Serkova; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2016-09-05       Impact factor: 4.784

4.  Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.

Authors:  Christina D Befani; Panagiotis J Vlachostergios; Eleana Hatzidaki; Anna Patrikidou; Sophia Bonanou; George Simos; Christos N Papandreou; Panagiotis Liakos
Journal:  J Mol Med (Berl)       Date:  2011-09-10       Impact factor: 4.599

5.  The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.

Authors:  L Wang; G Song; X Chang; W Tan; J Pan; X Zhu; Z Liu; M Qi; J Yu; B Han
Journal:  Oncogene       Date:  2014-12-15       Impact factor: 9.867

6.  Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells.

Authors:  Giovanna Danza; Claudia Di Serio; Fabiana Rosati; Giuseppe Lonetto; Niccolò Sturli; Doreen Kacer; Antonio Pennella; Giuseppina Ventimiglia; Riccardo Barucci; Annamaria Piscazzi; Igor Prudovsky; Matteo Landriscina; Niccolò Marchionni; Francesca Tarantini
Journal:  Mol Cancer Res       Date:  2011-12-15       Impact factor: 5.852

7.  Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.

Authors:  W Zhai; Y Sun; M Jiang; M Wang; T A Gasiewicz; J Zheng; C Chang
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

8.  Coordinated action of hypoxia-inducible factor-1α and β-catenin in androgen receptor signaling.

Authors:  Takakazu Mitani; Naoki Harada; Yoshihisa Nakano; Hiroshi Inui; Ryoichi Yamaji
Journal:  J Biol Chem       Date:  2012-08-03       Impact factor: 5.157

9.  Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.

Authors:  Elizabeth V Nguyen; Margaret M Centenera; Max Moldovan; Rajdeep Das; Swati Irani; Andrew D Vincent; Howard Chan; Lisa G Horvath; David J Lynn; Roger J Daly; Lisa M Butler
Journal:  Mol Cell Proteomics       Date:  2018-04-09       Impact factor: 5.911

Review 10.  Involvement of androgens in ovarian health and disease.

Authors:  M Lebbe; T K Woodruff
Journal:  Mol Hum Reprod       Date:  2013-09-10       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.